OptiNose adds three to operations, regulatory affairs and commercialization
Thursday, June 12, 2014
OptiNose, a global specialty pharmaceuticals company, has announced three appointments to the company’s senior management team.
Ramona Lloyd, Ph.D. has joined the company as vice president, Regulatory Affairs and Quality. Lloyd has held executive leadership positions in Regulatory Affairs and Quality with such companies as Sanofi-Aventis, Bristol-Myers Squibb and Johnson & Johnson. She acted as senior vice president of Regulatory Affairs and Safety for ImClone Systems, a wholly-owned subsidiary of Eli Lilly.
Sheila Bergey has joined the company as vice president, Operations & Program Management. Bergey spent 25 years with Johnson & Johnson where she held leadership positions in Operations, Supply Chain and Change Management, including Strategic Planning, Program Management, Information Technology, Process Excellence and Procurement. She founded Saybrook Consulting and was appointed chief operating officer of Lindi Skin, a skin care company in the Philadelphia area. Most recently, Bergey was with MannKind, a bio-pharmaceutical company focused on developing drug-device combination product technologies.
Terrence Terifay has joined the company as senior vice president and chief commercial officer. Most recently, Terifay held commercial leadership positions at Mallinckrodt, including vice president, Marketing and interim general manager, Branded Specialty Pharmaceuticals. Previously, he was the executive vice president, chief operating officer, Synchrony Healthcare Group. He has also held positions of leadership and roles with increasing responsibility at Cephalon, Purdue Pharma and Johnson & Johnson.